Home » Stocks » Chinook Therapeutics

Chinook Therapeutics, Inc. (KDNY)

Stock Price: $15.43 USD 0.00 (0.00%)
Updated Oct 23, 2020 1:27 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 250.48M
Revenue (ttm) 27.96M
Net Income (ttm) -64.56M
Shares Out 16.23M
EPS (ttm) -4.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $15.43
Previous Close $15.43
Change ($) 0.00
Change (%) 0.00%
Day's Open 15.55
Day's Range 15.00 - 15.60
Day's Volume 19,067
52-Week Range 4.51 - 20.20

More Stats

Market Cap 250.48M
Enterprise Value 111.48M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.23M
Float 8.82M
EPS (basic) -4.00
EPS (diluted) -4.00
FCF / Share -4.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.17M
Short Ratio 0.00
Short % of Float 35.92%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.96
PB Ratio 5.37
Revenue 27.96M
Operating Income -76.26M
Net Income -64.56M
Free Cash Flow -67.09M
Net Cash 139.00M
Net Cash / Share 8.56
Gross Margin 100.00%
Operating Margin -272.79%
Profit Margin -230.90%
FCF Margin -239.98%
ROA n/a
ROE n/a
ROIC -38.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(76.60% upside)
Current: $15.43
Target: 27.25
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth14.39%-12.48%-65.99%-30.55%445.07%1517.03%-
Gross Profit17.2615.0917.2450.6872.9813.390.83
Operating Income-90.14-101-106-71.86-13.56-19.12-14.54
Net Income-82.37-95.36-91.86-91.15-39.21-17.01-16.05
Shares Outstanding16.0215.7614.5813.048.940.060.06
Earnings Per Share-5.15-6.05-6.30-7.00-4.40-265.30-279.00
Operating Cash Flow-65.51-68.76-88.86-86.0815519.37-14.23
Capital Expenditures-1.26-2.32-5.15-23.89-2.17-0.78-0.17
Free Cash Flow-66.77-71.08-94.01-11015318.58-14.40
Cash & Equivalents2142673273484161198.53
Total Debt33.44-----12.99
Net Cash / Debt181267327348416119-4.46
Book Value65.60135237227262-61.30-38.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Chinook Therapeutics, Inc.
Country United States
Employees 43
CEO Eric L. Dobmeier

Stock Information

Ticker Symbol KDNY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KDNY


Chinook Therapeutics, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.